DNA hypermethylation of a selective gene panel as a risk marker for colon cancer in patients with ulcerative colitis

International Journal of Molecular Medicine

Volumn 31, Issue 5, 2013, Pages 1255-1261

  Kim, Tae Oh ^a   Park, Jongha ^a   Kang, Myoung Joo ^a   Lee, Sang Heon ^a   Jee, Sam Ryong ^a   Ryu, Dong Yup ^b   Yang, Kwangmo ^c   Yi, Joo Mi ^c  

^a Inje University College of Medicine   (South Korea)

^b Pusan National University School of Medicine   (South Korea)

^c Dongnam Institute of Radiological and Medical Science   (South Korea)

Author keywords

DNA methylation; Risk marker; Ulcerative colitis

Indexed keywords

FIBRILLIN 2; SECRETED FRIZZLED RELATED PROTEIN 1; TISSUE FACTOR PATHWAY INHIBITOR; TRANSCRIPTION ELONGATION REGULATOR 1 LIKE PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER GROWTH; CANCER RISK; CLINICAL ARTICLE; COLON CANCER; CONTROLLED STUDY; DNA METHYLATION; FEMALE; GENE FREQUENCY; GENE IDENTIFICATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; LIMIT OF QUANTITATION; MALE; PRIORITY JOURNAL; TRANSCRIPTION ELONGATION; TRANSCRIPTION REGULATION; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGE DISTRIBUTION; COLITIS, ULCERATIVE; COLONIC NEOPLASMS; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENES, NEOPLASM; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; SEQUENCE ANALYSIS, DNA; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84876105622     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2013.1317     Document Type: Article

References (36)

1. Ekbom A, Helmick C, Zack M and Adami HO: Increased risk of large-bowel cancer in Crohn's disease with colonic involvement. Lancet 336: 357-359, 1990.
2. Ekbom A, Helmick C, Zack M and Adami HO: Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 323: 1228-1233, 1990.
3. Brentnall TA: Risk factors for development of colorectal cancer in inflammatory bowel disease. In: Advances in Inflammatory Bowel Disease. Norwell M (ed). Kluwer Academic Publishers, Norwell, MA, pp159-167, 1998.
4. Brentnall TA, Crispin DA, Rabinovitch PS, Haggitt RC, Rubin CE, Stevens AC and Burmer GC: Mutations in the p53 gene: An early marker of neoplastic progression in ulcerative colitis. Gastroenterology 107: 369-378, 1994.
5. Rabinovitch PS, Dziadon S, Brentnall TA, Emond MJ, Crispin DA, Haggitt RC and Bronner MP: Pancolonic chromosomal instability precedes dysplasia and cancer in ulcerative colitis. Cancer Res 59: 5148-5153, 1999.
6. Harpaz N and Talbot IC: Colorectal cancer in idiopathic inflammatory bowel disease. Semin Diagn Pathol 13: 339-357, 1996.
7. Eaden JA, Abrams KR and Mayberry JF: The risk of colorectal cancer in ulcerative colitis: A meta-analysis. Gut 48: 526-535, 2001.
8. Rutter MD, Saunders BP, Wilkinson KH, Rumbles S, Schofield G, Kamm MA, Williams CB, Price AB, Talbot IC and Forbes A: Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology 130: 1030-1038, 2006.
9. Riddell RH, Goldman H, Ransohoff DF, Appelman HD, Fenoglio CM, Haggitt RC, Ahren C, Correa P, Hamilton SR, Morson BC, Sommers SC and Yardley JH: Dysplasia in inflammtory bowel disease: Standardized classification with provisional clinical applications. Hum Pathol 14: 931-968, 1983.
10. Jones PA and Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428, 2002.
11. Esteller M: Epigenetic gene silencing in cancer: The DNA hypermethylome. Hum Mol Genet 16: R50-R59, 2007.
12. Tominaga K, Fujii S, Mukawa K, Fujita M, Ichikawa K, Tomita S, Imai Y, Kanke K, Ono Y, Terano A, Hiraishi H and Fujimori T: Prediction of colorectal neoplasia by quantitative methylation analysis of estrogen receptor gene in nonneoplastic epithelium from patients with ulcerative colitis. Clin Cancer Res 11: 8880-8885, 2005.
13. Sato F, Shibata D, Harpaz N, Xu Y, Yin J, Mori Y, Wang S, Olaru A, Deacu E, Selaru FM, Kimos MC, Hytiroglou P, et al: Aberrant methylation of the HPP1 gene in ulcerative colitis-associated colorectal carcinoma. Cancer Res 62: 6820-6822, 2002.
14. Maekita T, Nakazawa K, Mihara M, Nakajima T, Yanaoka K, Iguchi M, Arii K, Kaneda A, Tsukamoto T, Tatematsu M, Tamura G, Saito D, et al: High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin Cancer Res 12: 989-995, 2006.
15. Nakajima T, Enomoto S, Yamashita S, Ando T, Nakanishi Y, Nakazawa K, Oda I, Gotoda T and Ushijima T: Persistence of a component of DNA methylation in gastric mucosae after Helicobacter pylori eradication. J Gastroenterol 45: 37-44, 2010.
16. Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD, Chen WD, Pretlow TP, Yang B, Akiyama Y, Van Engeland M, Toyota M, Tokino T, et al: Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 36: 417-422, 2004.
17. Schuebel KE, Chen W, Cope L, Glöckner SC, Suzuki H, Yi JM, Chan TA, Van Neste L, Van Criekinge W, van den Bosch S, van Engeland M, Ting AH, et al: Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet 3: 1709-1723, 2007.
18. Glöckner SC, Dhir M, Yi JM, McGarvey KE, Van Neste L, Louwagie J, Chan TA, Kleeberger W, de Bruïne AP, Smits KM, Khalid-de Bakker CA, Jonkers DM, et al: Methylation of TFPI2 in stool DNA: A potential novel biomarker for the detection of colorectal cancer. Cancer Res 69: 4691-4699, 2009.
19. Yi JM, Dhir M, Van Neste L, Downing SR, Jeschke J, Glöckner SC, de Freitas Calmon M, Hooker CM, Funes JM, Boshoff C, Smits KM, van Engeland M, et al: Genomic and epigenomic integration identifies a prognostic signature in colon cancer. Clin Cancer Res 17: 1535-1545, 2011.
20. Podolsky DK: Inflammatory bowel disease (1). N Engl J Med 325: 928-937, 1991.
21. Langholz E, Munkholm P, Davidsen M and Binder V: Course of ulcerative colitis: Analysis of changes in disease activity over years. Gastroenterology 107: 3-11, 1994.
22. Herman JG, Graff JR, Myohanen S, Nelkin BD and Baylin SB: Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93: 9821-9826, 1996.
23. Rhee I, Bachman KE, Park BH, Jair KW, Yen RW, Schuebel KE, Cui H, Feinberg AP, Lengauer C, Kinzler KW, Baylin SB and Vogelstein B: DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 416: 552-556, 2002.
24. Fleisher AS, Esteller M, Harpaz N, Leytin A, Rashid A, Xu Y, Liang J, Stine OC, Yin J, Zou TT, Abraham JM, Kong D, et al: Microsatellite instability in inflammatory bowel disease-associated neoplastic lesions is associated with hypermethylation and diminished expression of the DNA mismatch repair gene, hMLH1. Cancer Res 60: 4864-4868, 2000.
25. Issa JP, Ahuja N, Toyota M, Bronner MP and Brentnall TA: Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res 61: 3573-3577, 2001.
26. Sato F, Harpaz N, Shibata D, Xu Y, Yin J, Mori Y, Zou TT, Wang S, Desai K, Leytin A, Selaru FM, Abraham JM and Meltzer SJ: Hypermethylation of the p14(ARF) gene in ulcerative colitis-associated colorectal carcinogenesis. Cancer Res 62: 1148-1151, 2002.
27. Fujii S, Tominaga K, Kitajima K, Takeda J, Kusaka T, Fujita M, Ichikawa K, Tomita S, Ohkura Y, Ono Y, Imura J, Chiba T and Fujimori T: Methylation of the oestrogen receptor gene in non-neoplastic epithelium as a marker of colorectal neoplasia risk in longstanding and extensive ulcerative colitis. Gut 54: 1287-1292, 2005.
28. Wang FY, Arisawa T, Tahara T, Takahama K, Watanabe M, Hirata I and Nakano H: Aberrant DNA methylation in ulcerative colitis without neoplasia. Hepatogastroenterology 55: 62-65, 2008.
29. Lin Z, Hegarty JP, Cappel JA, Yu W, Chen X, Faber P, Wang Y, Kelly AA, Poritz LS, Peterson BZ, Schreiber S, Fan JB and Koltun WA: Identification of disease-associated DNA methylation in intestinal tissues from patients with inflammatory bowel disease. Clin Genet 80: 59-67, 2011.
30. Saito S, Kato J, Hiraoka S, Horii J, Suzuki H, Higashi R, Kaji E, Kondo Y and Yamamoto K: DNA methylation of colon mucosa in ulcerative colitis patients: Correlation with inflammatory status. Inflamm Bowel Dis 17: 1955-1965, 2011.
31. Yi JM, Dhir M, Guzzetta AA, Iacobuzio-Donahue CA, Heo K, Yang KM, Suzuki H, Toyota M, Kim HM and Ahuja N: DNA methylation biomarker candidates for early detection of colon cancer. Tumor Biol 33: 363-372, 2012.
32. Suzuki H, Gabrielson E, Chen W, Anbazhagan R, van Engeland M, Weijenberg MP, Herman JG and Baylin SB: A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 31: 141-149, 2002.
33. Stoehr R, Wissmann C, Suzuki H, Knuechel R, Krieg RC, Klopocki E, Dahl E, Wild P, Blaszyk H, Sauter G, Simon R, Schmitt R, et al: Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer. Lab Invest 84: 465-478, 2004.
34. Lodygin D, Epanchintsev A, Menssen A, Diebold J and Hermeking H: Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res 65: 4218-4227, 2005.
35. Fukui T, Kondo M, Ito G, Maeda O, Sato N, Yoshioka H, Yokoi K, Ueda Y, Shimokata K and Sekido Y: Transcriptional silencing of secreted frizzled related protein 1 (SFRP1) by promoter hypermethylation in non-small-cell lung cancer. Oncogene 24: 6323-6327, 2005.
36. Suzuki H, Toyota M, Carraway H, Gabrielson E, Ohmura T, Fujikane T, Nishikawa N, Sogabe Y, Nojima M, Sonoda T, Mori M, Hirata K, et al: Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer. Br J Cancer 98: 1147-1156, 2008.